心血管

订阅

MedSci主页 / 所有栏目 / 心血管

131亿美元！BMS完成对MyoKardia的收购，获得心血管特效药mavacamten

2020-11-18 MedSci原创 MedSci原创

Mavacamten阻塞型肥厚性心肌病（HCM）
关注

在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。

Bristol Myers Squibb（BMS）已完成了131亿美元收购MyoKardia的交易，用来增强其心血管疾病的研发管线。

收购完成后，BMS现在获得了MyoKardia的特效药mavacamten，该药物目前正在开发用于治疗阻塞型肥厚性心肌病（HCM）。Mavacamten把靶向肌节收缩蛋白的小分子抑制剂。

Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy - ScienceDirect

在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。与安慰剂相比，使用mavacamten的患者运动后LVOT梯度的降低更大，症状评分也更高。

图片来源：Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2020 Sep 12;396(10253):759-769.

取得积极成果之后，BMS计划在2021年第一季度向美国食品和药物管理局（FDA）提交新药申请。BMS还计划进一步探索mavacamten在非阻塞性HCM中的治疗潜力。

除了mavacamten之外，BMS还将开发MyoKardia的新型化合物产品线，包括两款临床阶段药物danicamtiv和MYK-224，以及两项临床前药物ACT-1和LUS-1。

BMS董事会主席兼首席执行官Giovanni Caforio表示：“我们很高兴欢迎MyoKardia同事来到Bristol Myers Squibb。 MyoKardia团队已经彻底改变了心血管治疗方法，我们期待着能够帮助更多的患者。”

原始出处：

http://www.pmlive.com/pharma_news/updated_bms_completes_$13.1bn_acquisition_of_myokardia_1352594

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (14)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1675367, encodeId=598016e5367c4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Thu Jan 07 21:29:07 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639658, encodeId=dfe51639658a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Mar 13 11:29:07 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651972, encodeId=54ed16519e24a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Feb 05 05:29:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925540, encodeId=29bc925540bf, content=厉害！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdc65325659, createdName=148ba795m17暂无昵称, createdTime=Fri Feb 19 21:07:02 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905195, encodeId=1b2790519513, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Sat Dec 05 15:56:24 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900365, encodeId=b69b19003651c, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 21 08:29:07 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901533, encodeId=810c9015331b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Mon Nov 23 19:30:51 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900770, encodeId=3f66900e706b, content=谢谢分享！！学习了！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68175436049, createdName=ms4000000754309719, createdTime=Fri Nov 20 13:39:01 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Nov 20 02:29:07 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900544, encodeId=61ca90054441, content=在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Nov 19 17:24:49 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2021-01-07 whmdzju

    #CAM#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1675367, encodeId=598016e5367c4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Thu Jan 07 21:29:07 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639658, encodeId=dfe51639658a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Mar 13 11:29:07 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651972, encodeId=54ed16519e24a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Feb 05 05:29:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925540, encodeId=29bc925540bf, content=厉害！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdc65325659, createdName=148ba795m17暂无昵称, createdTime=Fri Feb 19 21:07:02 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905195, encodeId=1b2790519513, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Sat Dec 05 15:56:24 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900365, encodeId=b69b19003651c, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 21 08:29:07 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901533, encodeId=810c9015331b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Mon Nov 23 19:30:51 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900770, encodeId=3f66900e706b, content=谢谢分享！！学习了！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68175436049, createdName=ms4000000754309719, createdTime=Fri Nov 20 13:39:01 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Nov 20 02:29:07 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900544, encodeId=61ca90054441, content=在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Nov 19 17:24:49 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2021-03-13 智者为医08

    #DIA#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1675367, encodeId=598016e5367c4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Thu Jan 07 21:29:07 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639658, encodeId=dfe51639658a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Mar 13 11:29:07 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651972, encodeId=54ed16519e24a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Feb 05 05:29:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925540, encodeId=29bc925540bf, content=厉害！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdc65325659, createdName=148ba795m17暂无昵称, createdTime=Fri Feb 19 21:07:02 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905195, encodeId=1b2790519513, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Sat Dec 05 15:56:24 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900365, encodeId=b69b19003651c, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 21 08:29:07 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901533, encodeId=810c9015331b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Mon Nov 23 19:30:51 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900770, encodeId=3f66900e706b, content=谢谢分享！！学习了！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68175436049, createdName=ms4000000754309719, createdTime=Fri Nov 20 13:39:01 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Nov 20 02:29:07 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900544, encodeId=61ca90054441, content=在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Nov 19 17:24:49 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2021-02-05 lishizhe

    #ACA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1675367, encodeId=598016e5367c4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Thu Jan 07 21:29:07 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639658, encodeId=dfe51639658a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Mar 13 11:29:07 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651972, encodeId=54ed16519e24a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Feb 05 05:29:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925540, encodeId=29bc925540bf, content=厉害！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdc65325659, createdName=148ba795m17暂无昵称, createdTime=Fri Feb 19 21:07:02 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905195, encodeId=1b2790519513, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Sat Dec 05 15:56:24 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900365, encodeId=b69b19003651c, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 21 08:29:07 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901533, encodeId=810c9015331b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Mon Nov 23 19:30:51 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900770, encodeId=3f66900e706b, content=谢谢分享！！学习了！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68175436049, createdName=ms4000000754309719, createdTime=Fri Nov 20 13:39:01 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Nov 20 02:29:07 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900544, encodeId=61ca90054441, content=在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Nov 19 17:24:49 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2021-02-19 148ba795m17暂无昵称

    厉害！！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1675367, encodeId=598016e5367c4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Thu Jan 07 21:29:07 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639658, encodeId=dfe51639658a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Mar 13 11:29:07 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651972, encodeId=54ed16519e24a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Feb 05 05:29:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925540, encodeId=29bc925540bf, content=厉害！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdc65325659, createdName=148ba795m17暂无昵称, createdTime=Fri Feb 19 21:07:02 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905195, encodeId=1b2790519513, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Sat Dec 05 15:56:24 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900365, encodeId=b69b19003651c, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 21 08:29:07 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901533, encodeId=810c9015331b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Mon Nov 23 19:30:51 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900770, encodeId=3f66900e706b, content=谢谢分享！！学习了！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68175436049, createdName=ms4000000754309719, createdTime=Fri Nov 20 13:39:01 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Nov 20 02:29:07 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900544, encodeId=61ca90054441, content=在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Nov 19 17:24:49 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2020-12-05 黛绿年华

    好

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1675367, encodeId=598016e5367c4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Thu Jan 07 21:29:07 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639658, encodeId=dfe51639658a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Mar 13 11:29:07 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651972, encodeId=54ed16519e24a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Feb 05 05:29:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925540, encodeId=29bc925540bf, content=厉害！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdc65325659, createdName=148ba795m17暂无昵称, createdTime=Fri Feb 19 21:07:02 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905195, encodeId=1b2790519513, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Sat Dec 05 15:56:24 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900365, encodeId=b69b19003651c, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 21 08:29:07 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901533, encodeId=810c9015331b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Mon Nov 23 19:30:51 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900770, encodeId=3f66900e706b, content=谢谢分享！！学习了！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68175436049, createdName=ms4000000754309719, createdTime=Fri Nov 20 13:39:01 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Nov 20 02:29:07 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900544, encodeId=61ca90054441, content=在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Nov 19 17:24:49 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2021-03-21 zhangj7108

    #特效药#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1675367, encodeId=598016e5367c4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Thu Jan 07 21:29:07 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639658, encodeId=dfe51639658a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Mar 13 11:29:07 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651972, encodeId=54ed16519e24a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Feb 05 05:29:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925540, encodeId=29bc925540bf, content=厉害！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdc65325659, createdName=148ba795m17暂无昵称, createdTime=Fri Feb 19 21:07:02 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905195, encodeId=1b2790519513, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Sat Dec 05 15:56:24 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900365, encodeId=b69b19003651c, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 21 08:29:07 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901533, encodeId=810c9015331b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Mon Nov 23 19:30:51 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900770, encodeId=3f66900e706b, content=谢谢分享！！学习了！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68175436049, createdName=ms4000000754309719, createdTime=Fri Nov 20 13:39:01 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Nov 20 02:29:07 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900544, encodeId=61ca90054441, content=在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Nov 19 17:24:49 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2020-11-23 黛绿年华

    厉害

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1675367, encodeId=598016e5367c4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Thu Jan 07 21:29:07 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639658, encodeId=dfe51639658a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Mar 13 11:29:07 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651972, encodeId=54ed16519e24a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Feb 05 05:29:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925540, encodeId=29bc925540bf, content=厉害！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdc65325659, createdName=148ba795m17暂无昵称, createdTime=Fri Feb 19 21:07:02 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905195, encodeId=1b2790519513, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Sat Dec 05 15:56:24 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900365, encodeId=b69b19003651c, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 21 08:29:07 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901533, encodeId=810c9015331b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Mon Nov 23 19:30:51 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900770, encodeId=3f66900e706b, content=谢谢分享！！学习了！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68175436049, createdName=ms4000000754309719, createdTime=Fri Nov 20 13:39:01 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Nov 20 02:29:07 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900544, encodeId=61ca90054441, content=在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Nov 19 17:24:49 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2020-11-20 ms4000000754309719

    谢谢分享！！学习了！！

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1675367, encodeId=598016e5367c4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Thu Jan 07 21:29:07 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639658, encodeId=dfe51639658a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Mar 13 11:29:07 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651972, encodeId=54ed16519e24a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Feb 05 05:29:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925540, encodeId=29bc925540bf, content=厉害！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdc65325659, createdName=148ba795m17暂无昵称, createdTime=Fri Feb 19 21:07:02 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905195, encodeId=1b2790519513, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Sat Dec 05 15:56:24 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900365, encodeId=b69b19003651c, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 21 08:29:07 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901533, encodeId=810c9015331b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Mon Nov 23 19:30:51 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900770, encodeId=3f66900e706b, content=谢谢分享！！学习了！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68175436049, createdName=ms4000000754309719, createdTime=Fri Nov 20 13:39:01 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Nov 20 02:29:07 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900544, encodeId=61ca90054441, content=在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Nov 19 17:24:49 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2020-11-20 canlab

    #BMS#

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1675367, encodeId=598016e5367c4, content=<a href='/topic/show?id=cb8a400091' target=_blank style='color:#2F92EE;'>#CAM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4000, encryptionId=cb8a400091, topicName=CAM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16ac27217804, createdName=whmdzju, createdTime=Thu Jan 07 21:29:07 CST 2021, time=2021-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1639658, encodeId=dfe51639658a9, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Sat Mar 13 11:29:07 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1651972, encodeId=54ed16519e24a, content=<a href='/topic/show?id=3a3e1e9504' target=_blank style='color:#2F92EE;'>#ACA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1795, encryptionId=3a3e1e9504, topicName=ACA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=843c24278901, createdName=lishizhe, createdTime=Fri Feb 05 05:29:07 CST 2021, time=2021-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=925540, encodeId=29bc925540bf, content=厉害！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fdc65325659, createdName=148ba795m17暂无昵称, createdTime=Fri Feb 19 21:07:02 CST 2021, time=2021-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=905195, encodeId=1b2790519513, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Sat Dec 05 15:56:24 CST 2020, time=2020-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900365, encodeId=b69b19003651c, content=<a href='/topic/show?id=258e6e97908' target=_blank style='color:#2F92EE;'>#特效药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=67979, encryptionId=258e6e97908, topicName=特效药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 21 08:29:07 CST 2021, time=2021-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=901533, encodeId=810c9015331b, content=厉害, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEIrIoKA6ro6CRnrVdQgZeVHMNOp9zBGDa4zbuUVatOhpScaygqRnJWeibItibcFFETwq4g7Q9z1LbGA/0, createdBy=81822151800, createdName=黛绿年华, createdTime=Mon Nov 23 19:30:51 CST 2020, time=2020-11-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900770, encodeId=3f66900e706b, content=谢谢分享！！学习了！！, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68175436049, createdName=ms4000000754309719, createdTime=Fri Nov 20 13:39:01 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378686, encodeId=83d913e8686cc, content=<a href='/topic/show?id=f238358866' target=_blank style='color:#2F92EE;'>#BMS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3588, encryptionId=f238358866, topicName=BMS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=512d422, createdName=canlab, createdTime=Fri Nov 20 02:29:07 CST 2020, time=2020-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=900544, encodeId=61ca90054441, content=在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Thu Nov 19 17:24:49 CST 2020, time=2020-11-19, status=1, ipAttribution=)]
    2020-11-19 咻凡

    在EXPLORER-HCM研究中，mavacamten达到了疾病症状和心脏功能复合评分改善的主要终点。

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

Lancet：心肌肌球蛋白抑制剂Mavacamten治疗梗阻性肥厚型心肌病！

心肌过度收缩是肥厚型心肌病的关键病理异常，并且是左心室流出道（LVOT）阻塞的主要决定因素。肥厚型心肌病的可用药物少且耐受性差，并且缺乏疾病特异性。本研究旨在评估心肌肌球蛋白抑制剂mavacamten